Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety

[Image: see text] The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we have developed a novel anticance...

Descripción completa

Detalles Bibliográficos
Autores principales: Borsari, Chiara, Rageot, Denise, Beaufils, Florent, Bohnacker, Thomas, Keles, Erhan, Buslov, Ivan, Melone, Anna, Sele, Alexander M., Hebeisen, Paul, Fabbro, Doriano, Hillmann, Petra, Wymann, Matthias P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792169/
https://www.ncbi.nlm.nih.gov/pubmed/31620236
http://dx.doi.org/10.1021/acsmedchemlett.9b00333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792169/
https://www.ncbi.nlm.nih.gov/pubmed/31620236
http://dx.doi.org/10.1021/acsmedchemlett.9b00333

Ejemplares similares